Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillis Carrigan

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 22, 2021
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type diseaseAlexander I Spira, Huakang Tu, Shivani Aggarwal, et al.
Clinical Pharmacology and Therapeutics|July 28, 2019
Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled TrialsGillis Carrigan, Samuel Whipple, William B Capra, et al.
The Journal of Allergy and Clinical Immunology|December 3, 2014
The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancyJennifer Namazy, Michael D Cabana, Angela E Scheuerle, et al.
BMC Medical Research Methodology|August 21, 2019
Validation of diagnosis codes to identify side of colon in an electronic health record registryPatricia Luhn, Deborah Kuk, Gillis Carrigan, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2024
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world studyHossein Borghaei, Xerxes Pundole, Laura Sangaré, et al.
The Journal of Allergy and Clinical Immunology|April 1, 2014
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabAidan Long, Abdelkader Rahmaoui, Kenneth J Rothman, et al.
Pharmacoepidemiology and Drug Safety|March 16, 2019
An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records databaseGillis Carrigan, Samuel Whipple, Michael D Taylor, et al.
Health Services Research|May 15, 2018
Development and Validation of a High-Quality Composite Real-World Mortality EndpointMelissa D Curtis, Sandra D Griffith, Melisa Tucker, et al.
The Journal of Allergy and Clinical Immunology|September 19, 2016
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthmaCarlos Iribarren, Abdelkader Rahmaoui, Aidan A Long, et al.
American Journal of Epidemiology|September 10, 2024
Emulations of oncology trials using real-world data: a systematic literature reviewJennifer R Rider, Asher Wasserman, Lukas Slipski, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Lung Cancer (Amsterdam, Netherlands)|July 22, 2021
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type diseaseAlexander I Spira, Huakang Tu, Shivani Aggarwal, et al.
Clinical Pharmacology and Therapeutics|July 28, 2019
Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled TrialsGillis Carrigan, Samuel Whipple, William B Capra, et al.
The Journal of Allergy and Clinical Immunology|December 3, 2014
The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancyJennifer Namazy, Michael D Cabana, Angela E Scheuerle, et al.
BMC Medical Research Methodology|August 21, 2019
Validation of diagnosis codes to identify side of colon in an electronic health record registryPatricia Luhn, Deborah Kuk, Gillis Carrigan, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2024
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world studyHossein Borghaei, Xerxes Pundole, Laura Sangaré, et al.
The Journal of Allergy and Clinical Immunology|April 1, 2014
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabAidan Long, Abdelkader Rahmaoui, Kenneth J Rothman, et al.
Pharmacoepidemiology and Drug Safety|March 16, 2019
An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records databaseGillis Carrigan, Samuel Whipple, Michael D Taylor, et al.
Health Services Research|May 15, 2018
Development and Validation of a High-Quality Composite Real-World Mortality EndpointMelissa D Curtis, Sandra D Griffith, Melisa Tucker, et al.
The Journal of Allergy and Clinical Immunology|September 19, 2016
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthmaCarlos Iribarren, Abdelkader Rahmaoui, Aidan A Long, et al.
American Journal of Epidemiology|September 10, 2024
Emulations of oncology trials using real-world data: a systematic literature reviewJennifer R Rider, Asher Wasserman, Lukas Slipski, et al.
Pageof 2